Despite substantial research efforts, the problems of spreading infectious diseases (such as COVID-19) through surface transmission and infections associated with medical devices persist. One promising solution is to apply a coating to the surface of concern that can provide effective surface disinfection. However, existing approaches typically provide only short-term disinfection effects (a few hours), contain materials having potential human or environmental health risks, or require specific fabrication steps that can be performed only during device manufacturing.
Chronic cough is a persistent daily cough that lasts greater than eight weeks and affects 10% of the general population. It is associated with a significant burden on health and quality of life. In clinical practice, there are very limited tools in order to quantitively monitor cough. Existing products are too expensive and labor intensive, making it impractical for use in day-to-day clinical practice. This project is aimed to create a quantitative way for clinicians to be able to diagnose, assess and monitor cough more efficiently.
Current testing for SARS-CoV-2 focuses on detection of the pathogen via isolated nucleic acids, routinely from nasopharyngeal swabs. To our knowledge, no approved clinical SARS-CoV-2 diagnostic tests using nasopharyngeal swabs incorporate measurements of host responses at the time of diagnosis. Monitoring host responses during SARS-CoV-2 infection is important, as stratification of COVID-19 patients based on host responses is predictive of mortality.
In order to meet Canada’s need for emissions-free hydrogen fuel, we aim to develop the Copper-Chlorine (Cu-Cl) thermochemical hydrogen production cycle into a pilot-plant which can be used to demonstrate the commercial feasibility of the process. An important portion of this development is research into how to integrate the Cu-Cl cycle with a waste heat source. By utilizing waste heat capture and upgrade, the Cu-Cl cycle can generate hydrogen fuel using energy that otherwise would be radiated into the environment.
Histone deacetylase 6 (HDAC6) is a protein known to be involved in a wide array of cancers. Although there are currently 4 approved HDAC inhibitors to date, these drugs lack the selectivity to only target HDAC6, given its high structural similarities with 10 other HDAC proteins, resulting in severe side-effects in patients such as nausea, diarrhea, and cardiac toxicities. Moreover, these approved drugs are also easily eliminated by the body, requiring the patients to take high doses frequently, further worsening the toxicity profile.
For people with mobility impairments, such as spinal cord injury survivors, rehabilitation and at home care settings come with the possibility of costly, painful pressure ulcers and skin breakdown. Occurring at a high frequency, current practice requires constant vigilance by caretakers and individuals using self-management practices. This injury comes from a prolonged application of pressures, temperatures and humid environments causing the skin to die from a lack of blood flow, usually from situations that an able-bodied person can avoid, but those with mobility impairments cannot.
One crucial difficulty with fast charging lithium-ion battery packs is the possibility of battery capacity deterioration if not properly managed. Fast charging electric vehicles for example, should involve ensuring that each one of the thousands of cells are charged safely and are balanced to all the other cells if the range of the vehicle is to be maintained for several years. The most common way to safely charge and balance cells involves a lot of wasted energy and suboptimal capacity saving methods.
The battery is considered as the source of power for electric transport. The performance of the battery drops at low temperature which reduces the mileage of Electric Vehicle (EV). This issue is hindering the widespread adoption of EV in cold places like Canada. The Low-Temperature Battery (LTB) can be used in EV to solve the low milage problem in extreme cold temperature, but its cost is around three times higher than the Normal Temperature Battery (NTB). So, using the LTB in an EV is not economically feasible.
Biological manufacturers are now starting to make chemicals and biological products (like proteins) by growing large amounts of microorganisms like bacteria or algae. One major quality control step in the manufacturing process is to check the genetic sequences of these microorganisms because they often not correctly made. This is due to the biological method for manipulating the sequences is not perfect. To check that the genetic sequences are correct, manufacturers typically send samples for DNA sequencing at international service providers.